Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
https://doi.org/10.14341/2072-0351-5636
Abstract
Type 2 diabetes mellitus is a disease in which traditional therapeutic strategies, such as optimization of the lifestyle, intake of metformin and sulfonylureasor glitazone prove secondarily inefficient in the short run. The discovery and use of new hypoglycemic agents, e.g. DPP-4 inhibitors, openup opportunities for the further improvement of glycemic control. This review contains data on mechanisms of action, efficacy and safety of DPP-4inhibitors exemplified by sitagliptin and their possible effects on the cardiovascular system.
About the Authors
Elena Nikolaevna Trunina
Medical Centre, Management Department of Presidential Administration, Moscow
Nina Alexandrovna Petunina
I.M.Sechenov First Moscow State Medical University, Moscow
Svetlana Alekseevna Chorbinskaya
Medical Centre, Management Department of Presidential Administration, Moscow
References
1. International Diabetes Federation. Diabetes prevalence. Available at http://www.idf.org/home/index.cfm?node=264.
2. Kahn S.E., Haffner S.M., Heise M.A. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. - 2006. - № 355(23). - Р. 2427-2443.
3. Ahren B. Gut peptides and type 2 diabetes mellitus treatment //Curr Diab Rep. - 2003. - № 3. - Р. 365-372.
4. Drucker D.J. Biological actions and therapeutic potential of the glucagonlike peptides // Gastroenterology. - 2002. - № 122. - Р. 531-544.
5. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans // Am. J. Physiol. - 2004. - № 287. - Р. E199-E206.
6. Meier J.J., Nauck M.A. Glucose-dependent insulinotropic polypeptide/ gastric inhibitory polypeptide // Best Pract. Res. Clin. Endocrinol. Metab. - 2004. - № 18. - Р. 587-606.
7. Toft-Nielsen M.B., Damholt M.B,. Madsbad S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients // J. Clin. Endocrinol Metab. - 2001. - № 86. - Р. 3717-3723.
8. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus // J. Clin. Invest. - 1993. - № 91. - Р. 301-307.
9. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor // Endocrinology. - 1996. - № 137. - Р. 2968-2978.
10. Campos R.V., Lee Y.C., Drucker D.J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagonlike peptide-1 in the mouse // Endocrinology. - 1994. - № 134. - Р. 2156-2164.
11. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 // Proc. Natl. Acad. Sci. USA. - 1992. - № 89. - Р. 8641-8645.
12. Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Pénicaud L., Drucker D.J., Magnan C., Burcelin R. Brain glucagon- like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity // Diabetes. - 2008. - № 57(10): 2577-2587.
13. Vila Petroff M.G., Egan J.M., Wang X., Sollott S.J. Glucagon-like peptide- 1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes // Circ. Res. - 2001. - № 89. - Р. 445-452.
14. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker D.J., Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor // Endocrinology. - 2003. - № 144. - Р. 2242-2252.
15. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury // Diabetes. - 2005. - № 54. - Р. 146-151.
16. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T., Shannon R.P. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts // J. Pharmacol. Exp. Ther. - 2006. - № 317. - Р. 1106-1113.
17. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy // Circulation. - 2004. - № 110. - Р. 955-961.
18. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion // Circulation. - 2004. - № 109. - Р. 962-965.
19. Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy // Am. J. Physiol Heart Circ Physiol. - 2005. - № 289. - Р. H2401-H2408.
20. Deacon C.F., Plamboeck A., Moller S., Holst J.J. GLP-1- (9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion // Am J Physiol Endocrinol Metab. - 2002. - № 282. - Р. E873-E879.
21. Meier J.J., Kemmeries G., Holst J.J., Nauck M.A. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects // Diabetes. - 2005. - № 54. - Р. 2212-2218.
22. Mafong D.D., Henry R.R. The role of incretins in cardiovascular control // Curr. Hypertens Rep. - 2009. - № 11(1). - Р. 18-22.
23. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon- like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure // J. Card. Fail. - 2006. - № 12(9). - Р. 694-699.
24. Zarich S.W. The role of intensive glycemic control in the management of patients who have acute myocardial infarction // Cardiol. Clin. - 2002. - № 3. - Р. 109-117.
25. Mu J., Zhou Y-P., Woods J. et al. Direct comparison of efficacy and durability of DPP-4 inhibitor, PPAR agonist and sulfonylurea on glycemic control and b-cell function in a rodent model of Type 2 diabetes. Presented at: American Diabetes Association 66th Annual Scientific Sessions. Washington, DC, USA, 9-13 June 2006 (Abstract 588-P).
26. Mu J., Woods J., Zhou Y.P.. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes // Diabetes. - 2006. - № 55. - Р. 1695-704.
27. Demuth H.U., McIntosh C.H., Pederson R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors // Biochim. Biophys. Acta. - 2005. - № 1751. - Р. 33-44.
28. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone // Diabetes Care. - 2006. - № 29 (12). - Р. 2638-2643.
29. Merck: Januvia™. www.januvia.com.
30. VanDeKoppel S., Choe H.M., Sweet B.V. Managed care perspective on three new agents for type 2 diabetes // J. Manag. Care Pharm. - 2008. - № 14(4). - Р. 363-380.
Review
For citations:
Trunina E.N., Petunina N.A., Chorbinskaya S.A. Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection. Diabetes mellitus. 2011;14(2):59-64. (In Russ.) https://doi.org/10.14341/2072-0351-5636
Views:
18931
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
